Analgesic effect of novel organogermanium compound, Ge-132.

Publisher Website
Google Scholar
Abstract
A novel organogermanium compound, Ge-132, carboxyethylgermanium sesquioxide, showed enhancement of 0.5 mg/kg morphine analgesia in both administration routes of oral administration (p.o.) and i.p. injection in the [rat] tail-flick test, and the effect was completely abolished by 0.5 mg/kg naloxone, stereospecific opiate antagonist. Ge-132 alone, 250 mg/kg i.p., did not show any antinociceptive action by assessing the tail-flick test and the hot-plate test. By the intracerebral injection of Ge-132, 100-1000 .mu.g, prolongation of tail-flick latency was observed and the action was abolished by 50 .mu.g CaCl2 injection. Although bestatin, which is reported to enhance the morphine analgesia, inhibits enkephalinase and enkephalin aminopeptidase, Ge-132 did not show any inhibition on both enkephalin degrading enzymes. The possibility for the mode of action of Ge-132 was discussed.